Prognostic performance of a two‐step method using the Fibro‐Scope system for metabolic dysfunction‐associated steatotic liver disease

Documenti analoghi

• Impact of PNPLA3 Genotype on Hepatic Steatosis Response to Pemafibrate in MASLD With Dyslipidemia
  di: Takao Shirono, et al.
  Pubblicazione: (2025)
• Combined effect of histological findings and diabetes mellitus on liver‐related events in patients with metabolic dysfunction‐associated steatotic liver disease
  di: Akihito Shiomi, et al.
  Pubblicazione: (2024)
• Association of liver fibrosis progression with non–liver‐related mortality in metabolic dysfunction‐associated steatotic liver disease
  di: Toshifumi Tada, et al.
  Pubblicazione: (2025)
• Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction‐associated steatotic liver disease
  di: Nobuharu Tamaki, et al.
  Pubblicazione: (2024)
• Validation study of age‐independent fibrosis score (Fibrosis‐3 index) in patients with metabolic dysfunction‐associated steatotic liver disease
  di: Kazuhiro Nouso, et al.
  Pubblicazione: (2024)